Theravance Biopharma
Stock Forecast, Prediction & Price Target
Theravance Biopharma (TBPH) stock Price Target by analysts
$10
Potential downside: -25.65%
Theravance Biopharma price prediction
What is Theravance Biopharma stock analysts` prediction?
Theravance Biopharma stock forecast: Based on 1 Wall Street analysts` predicted price targets for Theravance Biopharma in the last 3 months, the avarage price target is $10, with a high forecast of $NaN. The average price target represents a -25.65% change from the last price of $13.45.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Theravance Biopharma stock Price Target by analysts
Full breakdown of analysts given Theravance Biopharma price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
David Risinger Leerink Partners | 0% 0/1 | 11 months ago | $10 -25.65% downside | $7.66 | StreetInsider | Previous targets (0) |
Douglas Tsao H.C. Wainwright | 0% 0/1 | about 1 year ago | $15 11.52% upside | $9.59 | TheFly | Previous targets (0) |
Julian Harrison BTIG | 0% 0/1 | over 1 year ago | $21 56.13% upside | $8.93 | StreetInsider | Previous targets (0) |
Unknown Leerink Partners | N/A | almost 3 years ago | $14 4.08% upside | $11.22 | Benzinga | N/A |
Theravance Biopharma Financial Estimates
Theravance Biopharma Revenue Estimates
Theravance Biopharma EBITDA Estimates
Theravance Biopharma Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $55.31M N/A | $51.34M -7.16% | $57.42M 11.83% | Avg: $98.71M Low: $87.48M High: $115.40M avg. 71.91% | Avg: $138.31M Low: $118.24M High: $171.19M avg. 40.11% | Avg: $169.99M Low: $145.32M High: $210.40M avg. 22.90% | Avg: $245.60M Low: $209.95M High: $303.97M avg. 44.47% |
Net Income
% change YoY
| $-199.42M N/A | $-92.82M 53.45% | $-55.19M 40.54% | Avg: $11.09M Low: $-33.73M High: $54.19M avg. 120.11% | Avg: $44.06M Low: $-43.13M High: $132.17M avg. 297.00% | Avg: $35.74M Low: $29.00M High: $46.79M avg. -18.88% | Avg: $93.14M Low: $75.57M High: $121.92M avg. 160.57% |
EBITDA
% change YoY
| $-132.54M N/A | $-70.57M 46.75% | $-40.86M 42.09% | Avg: $-92.82M Low: $-108.51M High: $-82.26M avg. -127.13% | Avg: $-130.05M Low: $-160.96M High: $-111.18M avg. -40.11% | Avg: $-159.84M Low: $-197.83M High: $-136.64M avg. -22.90% | Avg: $-230.93M Low: $-285.82M High: $-197.41M avg. -44.47% |
EPS
% change YoY
| -$2.87 N/A | -$1.26 56.09% | -$1 20.63% | Avg: $0.21 Low: -$0.61 High: $0.98 avg. 120.75% | Avg: $0.86 Low: -$0.78 High: $2.39 avg. 312.04% | Avg: $0.65 Low: $0.52 High: $0.85 avg. -24.40% | Avg: $1.68 Low: $1.37 High: $2.2 avg. 160.57% |
Operating Expenses
% change YoY
| $292.95M N/A | $130.46M -55.46% | $113.45M -13.03% | Avg: $143.71M Low: $127.36M High: $168.00M avg. 26.67% | Avg: $201.37M Low: $172.14M High: $249.23M avg. 40.11% | Avg: $247.49M Low: $211.57M High: $306.31M avg. 22.90% | Avg: $357.56M Low: $305.67M High: $442.54M avg. 44.47% |
FAQ
What is Theravance Biopharma stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 139.70% in 2025-2028.
We have gathered data from 3 analysts. Their low estimate is -33.73M, average is 11.09M and high is 54.19M.
What is Theravance Biopharma stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 44.85% in 2025-2028.
We have gathered data from 3 analysts. Their low revenue estimate is $87.48M, average is $98.71M and high is $115.40M.
What is Theravance Biopharma stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 142.24% in 2025-2028.
We have gathered data from 3 analysts. Their low earnings per share estimate is -$0.61, average is $0.21 and high is $0.98.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering Theravance Biopharma stock. The most successful analyst is David Risinger.